Filing Flows › GSK (GSK) › R&D spending
GSK (GSK) R&D spending by quarter
GSK's R&D spending was $2.0B in Q3 2026 (third quarter 2026), -43% from Q2 2026. Over the last 3 quarters it ranged from $1.5B (Q3 2024) to $3.5B (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.0B | -43% | — |
| Q2 2026 | $3.5B | +138% | — |
| Q3 2024 | $1.5B | — | — |
Q3 2026 at a glance
GSK, Q3 2026: revenue $8.9B (+4% year over year), operating margin 23.9%, net earnings $1.5B, operating cash flow $3.1B. The chart follows the revenue to costs, profit and cash.
Questions
What is GSK's R&D spending?
GSK's R&D spending was $2.0B in Q3 2026 (third quarter 2026), -43% from Q2 2026.
How has GSK's R&D spending changed?
Over the last 3 quarters it ranged from $1.5B (Q3 2024) to $3.5B (Q2 2026).